Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944707 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03944707 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT03944707, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This was a proof-of-concept study to evaluate the efficacy of LOU064 in patients with inadequately controlled asthma. All subjects were randomized with 3:2 ratio to receive LOU064 100 mg once daily or LOU064 matching placebo for 12 weeks with standard background therapy of budesonide 80 µg/formoterol 4.5 µg two inhalations twice a day (b.i.d).
Interventions
- DRUG Placebo
- DRUG LOU064 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944707
The ClinicalTrials.gov registry entry for NCT03944707 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03944707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03944707 about?
NCT03944707 is a clinical study titled "Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients". This was a proof-of-concept study to evaluate the efficacy of LOU064 in patients with inadequately controlled asthma. All subjects were randomized with 3:2 ratio to receive LOU064 100 mg once daily or LOU064 matching placebo for 12 weeks with standard background therapy of budesonide 80 µg/formotero...
What is the current status of trial NCT03944707?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2019-07-18. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT03944707?
The interventions under investigation include: Placebo (DRUG), LOU064 100 mg (DRUG).
Who is sponsoring clinical trial NCT03944707?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.